ArticleCellular oncology (Dordrecht, Netherlands)2026
USP10 confers lenvatinib resistance in hepatocellular carcinoma by deubiquitinating the GPX2.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLenvatinib is a first-line treatment for advanced hepatocellular carcinoma (HCC), yet the development of resistance constitutes a major therapeutic obstacle. While Ubiquitin-specific peptidase 10 (USP10) has been implicated in cancer progression, its specific role in lenvatinib resistance remains unclear.
methodsUsing lentiviral transduction, we established HCC cell lines with stable USP10 overexpression or knockdown. The role of USP10 was further investigated using the selective inhibitor Spautin-1. Cell viability and proliferation were assessed via CCK-8 and colony formation assays. Apoptosis and reactive oxygen species (ROS) levels were measured. A xenograft mouse model was generated by subcutaneously injecting PLC/8024 cells into nude mice to evaluate tumor growth and drug response in vivo. Mechanistic insights were gained through co-immunoprecipitation, ubiquitination assays, RNA sequencing, and bioinformatics analysis.
resultsWe identified USP10 as a critical driver of lenvatinib resistance in HCC. Genetic silencing or pharmacological inhibition of USP10 suppressed tumor growth and restored lenvatinib sensitivity both in vitro and in vivo. Mechanistically, USP10 directly binds to and deubiquitinates glutathione peroxidase 2 (GPX2), enhancing its protein stability. This USP10/GPX2 axis scavenges intracellular ROS, thereby inhibiting apoptosis and promoting HCC cell survival and proliferation under lenvatinib treatment. DISCUSSIONS: Our findings reveal a novel USP10/GPX2 signaling pathway that confers lenvatinib resistance in HCC by mitigating oxidative stress. Targeting USP10 presents a promising therapeutic strategy to overcome resistance and improve outcomes for patients with advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.